MX2021012313A - Formas cristalinas de un inhibidor de trpc de piridazinona. - Google Patents

Formas cristalinas de un inhibidor de trpc de piridazinona.

Info

Publication number
MX2021012313A
MX2021012313A MX2021012313A MX2021012313A MX2021012313A MX 2021012313 A MX2021012313 A MX 2021012313A MX 2021012313 A MX2021012313 A MX 2021012313A MX 2021012313 A MX2021012313 A MX 2021012313A MX 2021012313 A MX2021012313 A MX 2021012313A
Authority
MX
Mexico
Prior art keywords
inhibitor
trpc
pyridazinone
crystal forms
compound
Prior art date
Application number
MX2021012313A
Other languages
English (en)
Spanish (es)
Inventor
Wenfeng Xue
Yuejun Gao
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of MX2021012313A publication Critical patent/MX2021012313A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MX2021012313A 2019-04-10 2020-04-10 Formas cristalinas de un inhibidor de trpc de piridazinona. MX2021012313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/081985 WO2020206623A1 (en) 2019-04-10 2019-04-10 Crystal forms
PCT/US2020/027689 WO2020210639A1 (en) 2019-04-10 2020-04-10 Crystal forms of a pyridazinone trpc inhibitor

Publications (1)

Publication Number Publication Date
MX2021012313A true MX2021012313A (es) 2021-11-17

Family

ID=70482847

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021012313A MX2021012313A (es) 2019-04-10 2020-04-10 Formas cristalinas de un inhibidor de trpc de piridazinona.
MX2025006384A MX2025006384A (es) 2019-04-10 2021-10-07 Formas cristalinas de un inhibidor de trpc de piridazinona

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025006384A MX2025006384A (es) 2019-04-10 2021-10-07 Formas cristalinas de un inhibidor de trpc de piridazinona

Country Status (10)

Country Link
US (1) US12655132B2 (cg-RX-API-DMAC7.html)
EP (1) EP3953352A1 (cg-RX-API-DMAC7.html)
JP (2) JP7738482B2 (cg-RX-API-DMAC7.html)
CN (2) CN114502552B (cg-RX-API-DMAC7.html)
AU (2) AU2020272030C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021018221A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136652A1 (cg-RX-API-DMAC7.html)
MA (1) MA55614A (cg-RX-API-DMAC7.html)
MX (2) MX2021012313A (cg-RX-API-DMAC7.html)
WO (2) WO2020206623A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12435078B2 (en) 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
LT3852533T (lt) * 2018-09-18 2024-06-10 Gfb (Abc), Llc Piridazinonai ir jų naudojimo būdai
WO2020206623A1 (en) 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
CA3136632A1 (en) 2019-04-11 2020-10-15 Goldfinch Bio, Inc. Spray-dried formulation of a pyridazinone trpc5 inhibitor
AU2020357178A1 (en) * 2019-10-04 2022-05-12 Gfb (Abc), Llc Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
KR102873922B1 (ko) 2020-07-03 2025-10-20 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리 화합물 및 이의 용도
JP7701559B2 (ja) * 2021-09-10 2025-07-01 メッドシャイン ディスカバリー インコーポレイテッド ハロゲン置換のピリダジノン系化合物及びその使用
EP4470540A4 (en) * 2022-01-27 2025-06-11 Wuhan Createrna Science and Technology Co.,Ltd. USE OF A HETEROCYCLIC COMPOUND
CN119546303A (zh) * 2022-08-05 2025-02-28 武汉朗来科技发展有限公司 包含杂环化合物的药物组合物及其制备方法和应用
WO2025250920A1 (en) 2024-05-31 2025-12-04 Gfb (Abc), Llc Pyridazinone phosphate compounds, pharmaceutical compositions, and medical uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP310798A0 (en) * 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
EP3180340B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
US12435078B2 (en) * 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
LT3852533T (lt) 2018-09-18 2024-06-10 Gfb (Abc), Llc Piridazinonai ir jų naudojimo būdai
WO2020206623A1 (en) 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
KR102873922B1 (ko) 2020-07-03 2025-10-20 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리 화합물 및 이의 용도

Also Published As

Publication number Publication date
JP7738482B2 (ja) 2025-09-12
EP3953352A1 (en) 2022-02-16
CA3136652A1 (en) 2020-10-15
WO2020206623A1 (en) 2020-10-15
BR112021018221A2 (pt) 2022-01-18
JP2022525759A (ja) 2022-05-19
MA55614A (fr) 2022-02-16
JP2026004294A (ja) 2026-01-14
MX2025006384A (es) 2025-07-01
AU2020272030C1 (en) 2026-05-07
US20220177455A1 (en) 2022-06-09
AU2020272030B2 (en) 2025-11-13
WO2020210639A1 (en) 2020-10-15
AU2026201003A1 (en) 2026-03-05
CN114502552A (zh) 2022-05-13
AU2020272030A1 (en) 2021-11-11
CN119264134A (zh) 2025-01-07
US12655132B2 (en) 2026-06-16
CN114502552B (zh) 2024-08-16

Similar Documents

Publication Publication Date Title
BR112021018221A2 (pt) Formas cristalinas de um inibidor de trpc de piridazinona
MX2021013662A (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
SA522431867B1 (ar) مثبطات كيناز بروتين-1 المتفاعل مع المستقبل غير متجانسة الحلقات
WO2020097537A3 (en) Fused ring compounds
EA202191177A1 (ru) 2-амино-n-гетероарилникотинамиды в качестве ингибиторов nav1.8
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
MX2022004143A (es) Compuesto que tiene actividad inhibidora de brd4, su método de preparación y su uso.
EA202091709A1 (ru) Ингибиторы днк-пк
EA202091708A1 (ru) Ингибиторы днк-пк
EA202092086A1 (ru) Ингибиторы аргиназы
MX2021002805A (es) Terapias de combinacion.
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
MX2022001940A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
EA202091372A1 (ru) Производное пирроло(пиразоло)пиримидина в качестве ингибитора lrrk2
EA201792214A1 (ru) Соединения замещенного хиназолина
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
CL2022001452A1 (es) Inhibidores de masp-2 y métodos de uso.
EA201890592A1 (ru) Жидкие фармацевтические композиции, содержащие ингибиторы sglt-2
MX2021010869A (es) Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
CO2021014260A2 (es) Formas sólidas de un inhibidor de glyt1
BR112021011325A2 (pt) Derivados de rapamicina
CL2019002840A1 (es) Formas cristalinas de (s)-afoxolaner.
MX2022000199A (es) Compuesto de pirazolona y pirimidina, y metodo de preparacion y uso del mismo.
BR112022020147A2 (pt) Compostos para tratar a doença de huntington
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.